BioPharmaceutical Business Intelligence

  • Analyze global market entry opportunities
  • Identify first generic entrants
  • Drug patents in 130+ countries
➤ Start Trial

or, See Plans & Pricing

Upgrade to enjoy subscriber-only features like email alerts and data export. See the Plans and Pricing

Serving leading biopharmaceutical companies globally:

Mallinckrodt
QuintilesIMS
Baxter
Argus Health
Cerilliant
Johnson and Johnson
Farmers Insurance
Express Scripts
Chubb
Colorcon

Generated: January 18, 2018

DrugPatentWatch Database Preview

Dr Reddys Labs Inc Company Profile

« Back to Dashboard

What is the competitive landscape for DR REDDYS LABS INC, and when can generic versions of DR REDDYS LABS INC drugs launch?

DR REDDYS LABS INC has forty-one approved drugs.

There are five US patents protecting DR REDDYS LABS INC drugs. There are two tentative approvals on DR REDDYS LABS INC drugs.

There are ninety-three patent family members on DR REDDYS LABS INC drugs in forty-eight countries and eighty-two supplementary protection certificates in thirteen countries.

Summary for Dr Reddys Labs Inc
International Patents:93
US Patents:5
Tradenames:34
Ingredients:26
NDAs:41

Drugs and US Patents for Dr Reddys Labs Inc

Applicant Tradename Generic Name Dosage NDA Approval Date TE Type RLD RS Patent No. Patent Expiration Product Substance Delist Req. Exclusivity Expiration
Dr Reddys Labs Inc NAPROXEN SODIUM naproxen sodium TABLET;ORAL 075168-001 Jul 28, 1998 OTC No No ➤ Subscribe ➤ Subscribe ➤ Subscribe
Dr Reddys Labs Inc AMOXIL amoxicillin TABLET, CHEWABLE;ORAL 050542-001 Approved Prior to Jan 1, 1982 DISCN Yes No ➤ Subscribe ➤ Subscribe ➤ Subscribe
Dr Reddys Labs Inc AUGMENTIN '400' amoxicillin; clavulanate potassium FOR SUSPENSION;ORAL 050725-002 May 31, 1996 DISCN Yes No ➤ Subscribe ➤ Subscribe ➤ Subscribe
Dr Reddys Labs Inc NEFAZODONE HYDROCHLORIDE nefazodone hydrochloride TABLET;ORAL 076309-002 Sep 16, 2003 BX RX No No ➤ Subscribe ➤ Subscribe ➤ Subscribe
Dr Reddys Labs Inc METFORMIN HYDROCHLORIDE metformin hydrochloride TABLET;ORAL 077787-002 Aug 23, 2006 AB RX No No ➤ Subscribe ➤ Subscribe ➤ Subscribe
Dr Reddys Labs Inc AUGMENTIN XR amoxicillin; clavulanate potassium TABLET, EXTENDED RELEASE;ORAL 050785-001 Sep 25, 2002 AB RX Yes Yes ➤ Subscribe ➤ Subscribe Y ➤ Subscribe
Dr Reddys Labs Inc SUMATRIPTAN SUCCINATE sumatriptan succinate TABLET;ORAL 076847-001 Aug 10, 2009 AB RX No No ➤ Subscribe ➤ Subscribe ➤ Subscribe
Dr Reddys Labs Inc AUGMENTIN XR amoxicillin; clavulanate potassium TABLET, EXTENDED RELEASE;ORAL 050785-001 Sep 25, 2002 AB RX Yes Yes ➤ Subscribe ➤ Subscribe ➤ Subscribe
Dr Reddys Labs Inc AUGMENTIN '250' amoxicillin; clavulanate potassium TABLET;ORAL 050564-001 Aug 6, 1984 DISCN Yes No ➤ Subscribe ➤ Subscribe ➤ Subscribe
Dr Reddys Labs Inc AMOXIL amoxicillin TABLET;ORAL 050754-002 Jul 10, 1998 DISCN Yes No ➤ Subscribe ➤ Subscribe ➤ Subscribe
Applicant Tradename Generic Name Dosage NDA Approval Date TE Type RLD RS Patent No. Patent Expiration Product Substance Delist Req. Exclusivity Expiration

This preview shows a limited data set. Subscribe for full access, or try a Free Trial

Paragraph IV (Patent) Challenges for DR REDDYS LABS INC drugs
Drugname Dosage Strength Tradename Submissiondate
➤ Subscribe Extended-release Tablets 1000 mg/62.5 mg ➤ Subscribe 1/21/2009

Non-Orange Book US Patents for Dr Reddys Labs Inc

For Orange Book-listed patents (shown in the main table above) generic applications must certify that the listed patents are expired, invalid, or will not be infringed by generic entry.

The non-Orange Book patents listed below do not require formal certifications, so they do not automatically impede generic entry. Instead, they represent potential opportunities for branded firms to block generic entry through patent infringment challenges.

Patent No. Title Estimated Patent Expiration
6,294,199 Method of treating a bacterial infection comprising administering amoxycillin ➤ Subscribe
6,660,299 Modified release pharmaceutical formulation comprising amoxycillin ➤ Subscribe
Patent No. Title Estimated Patent Expiration

This preview shows a limited data set. Subscribe for full access, or try a Free Trial

International Patents for Dr Reddys Labs Inc Drugs

Supplementary Protection Certificates for Dr Reddys Labs Inc Drugs

Supplementary Protection Certificate SPC Country SPC Expiration SPC Description
2014 00037 Denmark ➤ Subscribe PRODUCT NAME: ET KOMBINATIONSPRODUKT AF DAPAGLIFLOZIN ELLER ET FARMACEUTISK ACCEPTABELT SALT DERAF, HERUNDER DAPAGLIFLOZINPROPANDIOLMONOHYDRAT OG METFORMIN ELLER SALTE DERAF, HERUNDER METFORMINHYDROCHLORID; REG. NO/DATE: EU/1/13/900 20140116
2013 00001 Denmark ➤ Subscribe PRODUCT NAME: 8-(3-AMINOPIPERIDIN-1-YL)-7-BUT-2-INYL-3-METHYL-1-(4-METHYLCHINAZOLIN-2-YLMETHYL)-3,7-DIHYDROPURIN-2,6-DION ENANTIOMERER OG SALTE DERAF - SAERLIGT LINAGLIPTIN - I KOMBINATION MED METFORMINHYDROCHLORID; REG. NO/DATE: EU/1/12/780/001-028 20120720
5006-2008 Slovakia ➤ Subscribe PRODUCT NAME: SITAGLIPTIN A METFORMIN; NAT. REG.NO/DATE: EU/1/08/455/001-014, EU/1/08/456/001-014, EU/1/08/457/001-014 20080716; FIRST REG.:CH 58450 01-03 20080408
0677 Netherlands ➤ Subscribe PRODUCT NAME: COMBINATIE VAN DAPAGLIFLOZINE OF EEN FARMACEUTISCH AANVAARDBAAR ZOUT DAARVAN EN METFORMINE OF EEN FARMACEITISCH AANVAARDBAAR ZOUT DAARVAN, ZOALS BESCHERMD DOOR HET BASISOCTROOI EP 1506211B1; REGISTRATION NO/DATE: EU/1/13/900 20140121
/2008 Austria ➤ Subscribe PRODUCT NAME: SITAGLIPTIN, GEGEBENENFALLS IN DER FORM EINES PHARMAZEUTISCH ANNEHMBAREN SALZES, INSBESONDERE ALS MONOPHOSPHAT, UND METFORMIN, GEGEBENENFALLS IN FORM EINES PHARMAZEUTISCH ANNEHMBAREN SALZES, INSBESONDERE DES HYDROCHLORIDS; NAT. REGISTRATION NO/DATE: EU/1/08/455/001-014, EU/1/08/456/001-014, EU/1/08/457/001-014 20080716; FIRST REGISTRATION: CH 58450 01-03 20080408
9 5017-2014 Slovakia ➤ Subscribe PRODUCT NAME: KOMBINACIA DAPAGLIFLOZINU ALEBO JEHO FARMACEUTICKY PRIJATELNYCH SOLI A METFORMINU ALEBO JEHO FARMACEUTICKY PRIJATELNYCH SOLI; REGISTRATION NO/DATE: EU/1/13/900/001 - EU/1/13/900/012 20140116
C0048 France ➤ Subscribe PRODUCT NAME: AMLODIPINE OU UN DE SES SELS D?ADDITION D?ACIDES PHARMACAUTIQUEMENT ACCEPTABLES/ ATORVASTATINE OU UN DE SES SELS PHARMACEUTIQUEMENT ACCEPTABLES; REGISTRATION NO/DATE IN FRANCE: NL 29929 DU 20050707; REGISTRATION NO/DATE AT EEC: NL 29929 DU 20050707
C0038 Belgium ➤ Subscribe PRODUCT NAME: RIVASTIGMINE; NAT. REGISTRATION NO/DATE: EU/1/98/066/001 19980512; FIRST REGISTRATION: CH 54275 01 19970731
90013-1 Sweden ➤ Subscribe PRODUCT NAME: NAPROXEN OCH ESOMEPRAZOL; NAT. REG. NO/DATE: MTNR 43248 20101203; FIRST REG.: GB PL 17901/0263 20101105
12/018 Ireland ➤ Subscribe PRODUCT NAME: ALISKIREN OR A PHARMACEUTICALLY ACCEPTABLE SALT THEREOF, AMLODIPINE OR A PHARMACEUTICALLY ACCEPTABLE SALT THEREOF AND HYDROCHLOROTHIAZIDE OR A PHARMACEUTICALLY ACCEPTABLE SALT THEREOF.; NAT REGISTRATION NO/DATE: EU/1/11/730/001-060 20111122; FIRST REGISTRATION NO/DATE: SWITZERLAND 6167801-6167805 20110705
Supplementary Protection Certificate SPC Country SPC Expiration SPC Description

This preview shows a limited data set. Subscribe for full access, or try a Free Trial

Similar Applicant Names
Applicants may be listed under multiple names.
Here is a list of applicants with similar names.

For more information try a trial or see the plans and pricing

Serving leading biopharmaceutical companies globally:

Covington
Medtronic
Fuji
Harvard Business School
Farmers Insurance
QuintilesIMS
Healthtrust
Teva
Cantor Fitzgerald

Drugs may be covered by multiple patents or regulatory protections. All trademarks and applicant names are the property of their respective owners or licensors. Although great care is taken in the proper and correct provision of this service, thinkBiotech LLC does not accept any responsibility for possible consequences of errors or omissions in the provided data. The data presented herein is for information purposes only. There is no warranty that the data contained herein is error free. thinkBiotech performs no independent verifification of facts as provided by public sources nor are attempts made to provide legal or investing advice. Any reliance on data provided herein is done solely at the discretion of the user. Users of this service are advised to seek professional advice and independent confirmation before considering acting on any of the provided information. thinkBiotech LLC reserves the right to amend, extend or withdraw any part or all of the offered service without notice.

botpot